



ANUH PHARMA LTD.

3-A, Shivsagar Estate, North Wing,
Dr. Annie Besant Road, Worli, **MUMBAI** - 400 018. **INDIA**
Tel. : 91-22-6622 7575 • Fax : 91-22-6622 7600 / 7500
E-Mail : anuh@sk1932.com • CIN: L24230MH1960PLC011586

8th February, 2019

To,
The Manager (Listing)
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Fort, Mumbai - 400 001

Sub: Submission of Unaudited Financial Results along with Limited Review Report for the third quarter & nine months ended 31st December, 2018

Ref: Scrip Code No. 506260

Dear Sir,

Pursuant to the provisions of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the following:

1. Unaudited Financial Results for the third quarter and nine months ended 31st December, 2018; and
2. Limited Review Report for the quarter ended 31st December, 2018.

You are requested to kindly take the same on record.

Thanking you,

Yours faithfully,

For **Anuh Pharma Limited**

A.S. Ambrale



Ashwini Ambrale
Company Secretary & Compliance Officer
(Membership No.: A32456)

Encl: As above



We Serve Since 1932

Factory : E-17/3 & 17/4, M.I.D.C., Tarapur, BOISAR, Dist. Palghar - 401 506, INDIA Tel.: 74100 55574 / 74100 55575

ANUH PHARMA LTD.

CIN: L24230MH1960PLC011586


Regd. Office : 3-A, North Wing, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai - 400018

Tel: +91 22 6622 7575; Fax: +91 22 6622 7600; Email: anuh@sk1932.com; Website: www.anuhpharma.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2018

(Rs. in Lakhs)

Sr. No.	Particulars	3 months ended	3 months ended	3 months ended	9 months ended	9 months ended	12 months ended
		31/12/2018	30/09/2018	31/12/2017	31/12/2018	31/12/2017	31/03/2018
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I.	Revenue from operations (Refer note. 2)	6,999.91	8,736.72	6,332.91	23,761.49	17,413.83	24,123.59
II.	Other income	123.99	147.23	156.87	385.96	584.64	738.98
III.	Total Revenue (I + II)	7,123.90	8,883.95	6,489.78	24,147.45	17,998.47	24,862.57
IV.	Expenses:						
	Cost of materials consumed	5,728.52	6,332.45	4,977.98	18,388.66	13,214.60	18,372.29
	Purchases of Stock-in-Trade	235.26	48.65	9.97	370.62	9.97	34.62
	Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(596.62)	46.96	(116.81)	(819.91)	(191.80)	(327.74)
	Employee benefits expense	237.04	273.79	217.52	748.71	639.18	900.11
	Finance costs	7.98	1.66	0.29	10.42	0.44	4.05
	Depreciation and amortization expense	42.38	36.90	44.37	114.50	131.00	183.15
	Excise duty	-	-	-	-	315.92	315.92
	Other expenses	757.97	1,188.18	687.78	2,898.40	2,018.24	3,038.46
	Total expenses (IV)	6,412.53	7,928.59	5,821.10	21,711.40	16,137.55	22,520.86
V.	Profit / (Loss) before exceptional and items and tax (III - IV)	711.37	955.36	668.68	2,436.05	1,860.92	2,341.71
VI.	Exceptional items	-	-	-	-	-	-
VII.	Profit / (Loss) before tax (V - VI)	711.37	955.36	668.68	2,436.05	1,860.92	2,341.71
VIII.	Tax expense:						
	(1) Current tax	175.00	250.80	177.00	638.60	493.00	686.00
	(2) Deferred tax	(3.50)	8.95	(1.71)	(7.74)	42.21	4.47
		171.50	259.75	175.29	630.86	535.21	690.47
IX.	Profit/(Loss) after Tax (VII-VIII)	539.87	695.61	493.39	1,805.19	1,325.71	1,651.24
X.	Other Comprehensive Income (net of Tax)						
	(i) Items that will not be reclassified to profit or loss	(11.89)	0.20	2.42	(11.72)	10.43	5.18
	(ii) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Other Comprehensive Income (net of Tax)	(11.89)	0.20	2.42	(11.72)	10.43	5.18
XI.	Total Comprehensive Income for the period (IX + X) (Comprising Profit / (Loss) and Other Comprehensive Income for the period)	527.98	695.82	495.81	1,793.47	1,336.14	1,656.42
	Paid up Equity Share Capital (Face value ₹ 5/- each)	1,252.80	1,252.80	1,252.80	1,252.80	1,252.80	1,252.80
	Other Equity (excluding revaluation reserves)						13,708.72
XII.	Earnings per equity share (Non annualised) (In Rs.)						
	(1) Basic	2.15	2.78	1.97	7.20	5.29	6.59
	(2) Diluted	2.15	2.78	1.97	7.20	5.29	6.59
See accompanying notes to the financial results							



1. The results of the quarter and nine months ended December 31, 2018 were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on February 08, 2019. They have been subjected to limited review by the Statutory Auditor.
2. Post implementation of Goods & Service Tax (GST) w.e.f. July 01, 2017, revenue from operations is disclosed net off GST, revenue from operations for the earlier periods included excise duty which is now subsumed in GST. Revenue from operations for the nine months ended December 31, 2017 and the year ended March 31, 2018 includes excise duty upto June 30, 2017. Hence, revenue from operations for the nine months ended December 31, 2018 is not comparable to those of previous periods reported.
3. The Company has identified Bulk drug and Chemicals as its only primary reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no-separate segment information has been provided.
4. Previous period's figures have been regrouped and reclassified, wherever necessary, to correspond with those of the current period.

For Anuh Pharma Limited



Bipin N. Shah
Managing Director
(DIN: 00083244)



Place : Mumbai
Dated : February 08, 2019

REVIEW REPORT TO THE BOARD OF DIRECTORS OF
ANUH PHARMA LIMITED

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Anuh Pharma Limited** ("the Company") for the quarter and nine months ended 31st December , 2018 ("the Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016.
2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial results based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For JAYANTILAL THAKKAR & CO.
CHARTERED ACCOUNTANTS
(FIRM REG. NO. 104133W)



V. A. Merchant

VIRAL A. MERCHANT
PARTNER

MEMBERSHIP NO. 116279

PLACE: Mumbai

DATE: 8th February, 2019